(NASDAQ: INDV) Indivior Pharmaceuticals's forecast annual revenue growth rate of 2.09% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Indivior Pharmaceuticals's revenue in 2026 is $1,239,000,000.On average, 9 Wall Street analysts forecast INDV's revenue for 2026 to be $147,952,181,286, with the lowest INDV revenue forecast at $137,946,961,926, and the highest INDV revenue forecast at $156,206,487,258. On average, 9 Wall Street analysts forecast INDV's revenue for 2027 to be $155,706,226,290, with the lowest INDV revenue forecast at $145,200,745,962, and the highest INDV revenue forecast at $167,337,293,796.
In 2028, INDV is forecast to generate $165,211,184,682 in revenue, with the lowest revenue forecast at $145,701,006,930 and the highest revenue forecast at $179,968,883,238.